No Data
No Data
Heard on the Street: Moderna Got a Boost From Bird Flu, but Don't Count Your Chicks -- WSJ
By David Wainer Vaccine stocks are back in vogue, at least for now. Moderna, BioNTech, CureVac and Novavax have added billions of dollars in combined market capitalization gains in recent days after
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $18
JMP Securities analyst Roy Buchanan maintains $CureVac(CVAC.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 33.0% and a tota
Buy Rating on CureVac: Positive Financial Outlook and Promising Vaccine Trials Fuel Optimism
Express News | CureVac's Cash And Cash Equivalents Position Of €300.2M As Of March 31, 2024; Reaffirming Cash Runway Into Fourth Quarter Of 2025
Express News | CureVac Reported Q1 2024 Pre-Tax Loss Of €69.9M Vs. €57.4M YoY
Tom2808 : Nvda better